HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Health OTC Drugs Market Intelligence

Get Real: Orbital’s Chris Bunniss On Real World Evidence’s Potential For OTC Innovation

  • Interviews

Executive Summary

Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.

You may also be interested in...



2020 In Review: HBW Insight’s Five Key Takeaways For The European OTC Industry

HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe. 

Rx-To-OTC Switch And RWE Key To Creating ‘Crisis Proof’ European Medicines System

Europe's self-care industry urges the European Commission to use Rx-to-OTC switch and real world evidence to widen access to OTC medicines in the region as part of its new pharmaceutical strategy. 

European Medicines Agency Commits To Promoting Real-World Data

The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.

Table

View full table

Related Content

HBW Insight
HBW Insight

Topics

Tags:
Health OTC Drugs Market Intelligence
Latest Headlines

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

See All
UsernamePublicRestriction

Register

RS150496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By